{"disease":{"id":"newly-diagnosed-multiple-myeloma","name":"newly diagnosed multiple myeloma"},"drugs":{"marketed":[{"drug_id":"thalidomide","indication_name":"Newly Diagnosed Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thalomid","generic_name":"THALIDOMIDE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"thalidomide","quality_score":67,"revenue":null,"mechanism":"Thalomid works by inhibiting the production of tumor necrosis factor, a protein that promotes inflammation and tumor growth."},{"drug_id":"chembl-chembl3545131","indication_name":"Newly Diagnosed Multiple Myeloma (Not Eligible for ASCT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ISATUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06679101","title":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT07296627","title":"Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07053436","title":"Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Multiple Myeloma Research Consortium","has_results":false},{"nct_id":"NCT07247097","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05561049","title":"Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT07087964","title":"Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Universiteit Antwerpen","has_results":false},{"nct_id":"NCT06324266","title":"Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Jinling Hospital, China","has_results":false},{"nct_id":"NCT05088330","title":"A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM","phase":"NA","overall_status":"UNKNOWN","enrollment_count":76,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05259553","title":"Biomarkers in Multiple Myeloma","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Centre Hospitalier Universitaire de Saint Etienne","has_results":false},{"nct_id":"NCT06103838","title":"18F-Fluciclovine PET/CT in Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06409702","title":"Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":59,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04653246","title":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"Jacob Laubach, MD","has_results":false},{"nct_id":"NCT06682156","title":"Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT01891643","title":"PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03733691","title":"Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Oncotherapeutics","has_results":false},{"nct_id":"NCT04348006","title":"Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Al-Rasheed University College","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}